Sage Therapeutic Stock In The News
| SAGE Stock | USD 5.00 0.03 0.60% |
Our overall analysis of Sage Therapeutic's news coverage and content from conventional and social sources shows investors' bearish mood towards Sage Therapeutic. The specific impact of Sage Therapeutic news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Sage Therapeutic's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Sage Therapeutic headlines in addition to utilizing other, more conventional financial analysis modules. Check out Sage Therapeutic Backtesting and Sage Therapeutic Hype Analysis. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.
Sage |
Sage Therapeutic Today Top News and Investor Outlook
Sage Therapeutic Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Sage and other traded companies coverage with news coverage. We help investors stay connected with Sage headlines for the 19th of December to make an informed investment decision based on correlating the impacts of news items on Sage Stock performance. Please note that trading solely based on the Sage Therapeutic hype is not for everyone as timely availability and quick action are needed to avoid losses.
Sage Therapeutic stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Sage earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Sage Therapeutic that are available to investors today. That information is available publicly through Sage media outlets and privately through word of mouth or via Sage internal channels. However, regardless of the origin, that massive amount of Sage data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sage Therapeutic news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sage Therapeutic relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sage Therapeutic's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sage Therapeutic alpha.
Sage Largest EPS Surprises
Earnings surprises can significantly impact Sage Therapeutic's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2014-11-11 | 2014-09-30 | -0.4 | -0.5 | -0.1 | 25 | ||
2015-02-27 | 2014-12-31 | -0.43 | -0.57 | -0.14 | 32 | ||
2015-05-14 | 2015-03-31 | -0.49 | -0.66 | -0.17 | 34 | ||
2017-08-03 | 2017-06-30 | -1.67 | -1.88 | -0.21 | 12 | ||
2015-08-12 | 2015-06-30 | -0.68 | -0.9 | -0.22 | 32 | ||
2018-02-22 | 2017-12-31 | -1.99 | -1.75 | 0.24 | 12 |
Sage Therapeutic Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Sage Therapeutic Stock. Current markets are strongly bearish. About 86% of major world exchanges and indexes are down. See today's market update for more information.
16th of December 2024
Sage Therapeutics SWOT analysis navigating challenges in CNS drug stock at investing.com
5th of December 2024
Sage Names FY24 Platinum Club for Partners Awards Winners for Exceptional Business Perform... at globenewswire.com
4th of December 2024
Sage and Village Capital Partner to Empower 165 Purpose-Driven Startups via 3-year Program at globenewswire.com
3rd of December 2024
Sage Intacct supports SMB growth with new enhancements and capabilities at globenewswire.com
29th of November 2024
Sage Therapeutics Board Member, Dr. Jeffrey M. Jonas, Announces Retirement at thelincolnianonline.com
26th of November 2024
Sage Therapeutics announces board member retirement at investing.com
21st of November 2024
Sage raised to sector perform by RBC in wake of drug failure at seekingalpha.com
20th of November 2024
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdo... at businesswire.com
14th of November 2024
SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japans Patent Offi... at accesswire.com
30th of October 2024
Sage to sunset first postpartum depression drug, focus on Zurzuvae at bizjournals.com
23rd of October 2024
Rosen Law Firm Urges Sage Therapeutics, Inc. Stockholders with Large Losses to Contact the... at businesswire.com
21st of October 2024
Sage Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi Korsinsky Before... at accesswire.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sage Therapeutic in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sage Therapeutic's short interest history, or implied volatility extrapolated from Sage Therapeutic options trading.
Check out Sage Therapeutic Backtesting and Sage Therapeutic Hype Analysis. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.57) | Revenue Per Share 1.76 | Quarterly Revenue Growth 3.371 | Return On Assets (0.30) | Return On Equity (0.49) |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.